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ABSTRACT 
Objective: The present study was design with an objective of developing a simple and rapid high performance liquid chromatography (HPLC) 
method for the determination of Efavirenz (EFA) in rat plasma.  
Methods: Chromatographic separation was achieved on C18 column using acetonitrile-50 mM potassium phosphate (55:45 v/v) as mobile phase at 
a flow rate of 1 ml/min and UV detection at 250 nm.  
Results: The retention time of EFA was found to be 13.2 min. The developed method was validated for linearity, limit of quantification (LOQ), limit 
of detection (LOD), Stability and selectivity. Linearity studies were found to be acceptable over the range of 5-50 μg/ml.  
Conclusion: The present analytical method was found to be specific, sensitive, accurate and precise for quantification of EFA in rat plasma. It can be 
successively applied for pharmacokinetics studies also. 
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INTRODUCTION 
The development of a large number of new antiretroviral agents and 
the increasing resistance of HIV virus has led to changes in the 
treatment of this infection. Therapeutic monitoring of these drugs is 
recommended in order to avoid or to delay resistance from the 
virus, to avoid the usually underestimated non-adherence and to 
manage drug interactions. In view of this, analytical methods have 
already been described to quantify single [1-6] and combined [7-10] 
anti-HIV agents in biological media. 
EFA (fig. 1) is a non-nucleoside reverse transcriptase inhibitor 
(NNRTI) of HIV-I is used in association with other antiretroviral 
agents in the treatment of HIV infection [11].  
 
 
Fig. 1: Chemical structure of EFA 
 
Literature survey reveled that number of HPLC methods for 
estimation of plasma EFA alone [12-16] and in combination with 
other antiretroviral agents [17-26] have been reported. While some 
of these methods involve cumbersome and lengthy extraction 
procedures [15, 16, 19, 21], few other methods have utilized a 
complex mobile phase [17, 21] or gradient mobile phase [18,25]. 
Sample pretreatment by liquid-liquid extraction with diethyl-ether 
[12, 14, 18, 26] or protein precipitation with acetonitrile [13, 23] has 
also been carried out in some methods. 
We have developed simple, sensitive and accurate HPLC method for 
determination and quantification of EFA following solid-phase 
extraction of plasma. In comparison to all above reported method, 
the validation result demonstrated a higher sensitivity and need for 
lower plasma volume. After validation, this assay was successfully 
applied to pharmacokinetics after administration EFA to rats and its 
results would be helpful for evaluating the clinical application of this 
drug. 
MATERIALS AND METHODS 
Chemicals 
Pure EFA was kindly supplied as the gift sample from Lupin 
Research Park Pvt. Ltd. Pune, India. Atorvastatin (fig. 2) was a kind 
gift from Lupin Research Park Pvt. Ltd. Pune, India. Acetonitrile 
(HPLC grade) was purchased from Merck (India) and potassium 
dihydrogen orthophosphate was purchased from Qualigens (India). 
Deionized water was processed through a Milli-Q water purification 
system (Millipore, USA).  
 
Fig. 2: Chemical structure of Atorvastatin 
 
Preparation of standard solution 
A standard stock solution was prepared by dissolving EFA in 
methanol with concentration 500 µg/ml. The standard solutions 
(n=6) were prepared by spiking drug free rat plasma with known 
amount of EFA ranging between 5-50 µg/ml. Six EFA concentrations 
were prepared (5, 10, 20, 30, 40, 50 µg/ml) as in house quality 
control and kept at-20 ºC until assay. 
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Sample preparation 
The rat plasma samples of 250 µl were transferred to tubes in which 
50 µl of atorvastatin (internal standard i.e. I. S.), 100 µl of EFA were 
added, followed by one milliliter of ethyl acetate. The samples were 
vortexed for 1 min. The samples were centrifuged at 7000 rpm and 
organic phase was evaporated to dryness. The dried residue was 
reconstituted with 100 µl of mobile phase and 20 µl was injected 
into the HPLC column. 
Chromatographic conditions 
The HPLC system was composed of UV/VIS detector (Jasco UV 975). 
Chromatographic separation was performed on a Hypersil ODS 
(250×4.6 mm i.d., 5 μm) column and protected by the guard column. 
The isocratic mobile phase composed of acetonitrile and 50 mM 
potassium phosphate (55:45 v/v) with 1.5% of triethylamine was 
used and pH was adjusted to 4.3 with orthophosphoric acid. The 
flow rate and the detection wavelength was 1 mL/min and 250 nm 
respectively. All determination was performed at ambient column 
temperature. The software used was Jasco BORWIN version 1.5 LC-
netll/ADC system. 
Linearity 
Calibration plots were constructed for EFA standard solutions by 
plotting the concentration of compounds versus peak area 
responses. Standard solutions containing 5 and 50 µg/ml of EFA in 
plasma were prepared and injected into the HPLC column. The 
calibration equation (y = mx+b) was calculated from the calibration 
curves. The regression equations were calculated from the 
calibration graphs with the standard deviations of the slope and 
value interception. 
Accuracy and precision  
Accuracy of the assay method was determined for both within-day 
and between-day variations using the six times analysis of the 
samples. Precision of the assay was determined by repeatability 
(within-day) and intermediate precision (between-day). 
Intermediate precision was assessed by comparing the assays on 
different days (6 days). All data were expressed as % CV (coefficient 
of variation). The acceptance value for precision and accuracy for 
each concentration should not exceed 15% of percentage of 
coefficient of variation (% CV) from the theoretical value.  
Detection and quantitation limits (sensitivity) 
LOD and LOQ were estimated from the signal-to-noise ratio. The 
detection limit was defined as the lowest concentration level 
resulting in a peak height of three times the baseline noise. The 
quantitation limit was defined as the lowest concentration level that 
provided a peak height with a signal-to-noise ratio higher than 10, 
with precision (% RSD) and accuracy (% bias) within±10%. 
Stability 
Stability of EFA was measured by preparing three replicates (n=3) of 
EFA samples at three different concentrations of 10, 20 and 30 
μg/ml, respectively. The stability of the samples was assessed by the 
percentage recovery based on criteria’s. The procedures were 
designed as follow; (a) 30 min at 50 ºC in plasma and 18 hr at 25 °C 
in mobile phase after solid-phase extraction. 
RESULTS AND DISCUSSION 
Linearity 
Calibration curves of EFA standard in rat plasma showed a linearity 
line over the range of 5-50 μg/ml. The data was consistent 
throughout the experiment which showed a consistency of 
coefficient, intercept and slope. The calibration curve gives R2
 
 of 
0.999 and y-interception was 0.0766 as shown in fig. 3. Peak height 
ratio of EFA and I. S. of calibration standards were proportional to 
the concentration of EFA in plasma over the range tested (5-50 
µg/ml). The results of the linearity of the method are presented in 
table 1.  
Table 1: Result of linearity of calibration of EFA 
Conc. (ug/ml) Area of EFA Area of I. S. Ratio 
5 110104.2 400900.6 0.274642 
10 336936.7 602078.6 0.559622 
20 791335.5 755243.1 1.047789 
30 1147214 770496.1 1.488929 
40 1492710 760635.9 1.96245 
50 2171868 903399.4 2.404107 
 
 
Fig. 3: Calibration curve of EFA 
 
Accuracy and precision 
The accuracy of this method was assessed by the determination of 
the percentage recovery of EFA in rat plasma for both between-day 
and within-day variations. Six different standard solutions of 
concentration in the range of 0.5 to 50 μg/ml were analyzed.  
The obtained result is summarized in table 2. Then the results 
obtained were summarized in table 2. The results described the 
accuracy of this method with a mean recovery of 97.03 % for 
within-day samples and 98.36% for between-day samples, 
respectively. 
 
Table 2: Within day and between day results expressed in mean±standard deviation (SD) and precision in coefficient of variation (% CV). 
Each data represents a set of triplicates 
Within-day 
Concentration (μg/ml) mean±SD (μg/ml) Accuracy (Recovery %) Precision (Repeatability) % CV 
10 5.2±0.8 96.02 6.5 
20 6.3±1.5 97.05 9.2 
30 7.1±1.9 98.02 1.7 
Between day 
10 5.4±0.9 97.01 6.8 
20 6.2±1.3 99.03 9.0 
30 8.1±2.4 99.04 2.1 
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We then assessed the precision of this method from the repeatability 
of three different standard solutions for six times in the same day 
(within-day). The intermediate precision used the same six standard 
solutions six times on different days (between-day).  
The precision is described by the percentage relative standard 
deviation (RSD). In table, the relative standard deviation for within-
day samples ranged from 1.7 to 9.2 % and between-day samples 
ranged from 2.1 to 9.0 % as stated in table 2. 
Selectivity 
Representative chromatograms of blank and spiked plasma samples 
showed no interfering endogenous substances neither with EFA nor 
with the I. S. Potentially co-administered drugs had retention times 
different from EFA or the I. S. and were not detected with the 
described bio-analytical method. The retention times for the drugs 
tested for interference are shown in fig. 4. The retention times for 
EFA, I. S., Atovaquone, Isoniazide and Saquinavir are given in table 2. 
 
Table 2: The retention time of drug and I. S 
Drug Retention time (min) 
Atovaquone Not Detected 
Isoniazide 2-3 





Fig. 4: Retention time of both EFA and I. S 
 
In this study, attempts were made to extract EFA from plasma using 
ethyl acetate using atorvastatin as I. S. and this has been reported so 
far. The present method has the advantages of being simple and a 
run time of 15 min, without any loss of analyte, and uses a small 
sample volume. The use of I. S. helped in monitoring the recovery of 
EFA from plasma. Under the chromatographic conditions described 
above, EFA was well separated as seen in the representative 
chromatograms. The retention times of the I. S. and EFA were 8.3 
and 13.2 min, respectively. Blank plasma samples did not give any 
peak at the retention time of EFA. 
Sensitivity 
Six different concentration of EFA were assayed to calculate the LOD 
and LOQ. LOD represent the lowest concentration that can be 
detected by the method, while LOQ is the lowest concentration that 
can be determined at an acceptable precision and accuracy. In this 
study, the LOD and LOQ for EFA analysis were found to be 0.10 
μg/ml and 0.30 μg/ml, respectively.  
Stability 
The stability of EFA under various conditions were determined. The 
recovery data was obtained by comparing the samples to the freshly 
prepared sample. The results of stability studies were within the 
acceptable range as shown in table 4. 
Pharmacokinetic study 
The method described was applied for the determination of EFA 
concentrations from rat plasma after receiving a single oral dose of EFA 
(30 mg). Fig. 6 presents the mean plasma concentrations of EFA at 
various time points (30 min, 1, 2, 3, 4, 5, 6, 12, 24 and 48 h) EFA was 
detectable up to 48 h after the dose. The plasma concentration of EFA 
shows maximum concentration (Cmax, fig. 7) of EFA at 2 hr to be 200 
µg/ml. 
 
Table 4: Stability of EFA (n=3) 
Storage conditions Concentration (µg/ml) Recovery (%) 
30 min at 50 ºC in plasma 10 91.8 
20 97.6 
30 94.6 





Fig. 6: Plasma EFA concentration in rats administered a single 
oral dose of 30 mg EFA 
 
Fig. 7: Maximum concentration (Cmax) of EFA in plasma at 2 hr 
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CONCLUSION 
Current HPLC method is a simple, sensitive, reliable and easily to 
applicable for determination and quantification of EFA in rat plasma. 
This method is suitable for studying the pharmacokinetic 
parameters of EFA in rat model. The analysis time was 15 min per 
sample. It was applied to a pharmacokinetic study of EFA. The 
applicability of method suggests its further application for 
bioequivalence, bioavailability, drug-drug interaction and clinical 
studies. 
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